Introduction of Christopher Cleary to the Orchestra BioMed Board
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is thrilled to announce a significant addition to its Board of Directors. Christopher Cleary, a monumental figure in the medical device industry, has joined the team as an independent member effective January 30, 2025. With over three decades of experience in corporate development and a robust background in mergers and acquisitions, Cleary's expertise aligns perfectly with the company's vision for innovation in medical technology.
Professional Background and Influence
Mr. Cleary's former role as Senior Vice President of Corporate Development at Medtronic plc established him as an influential leader within the sector. His track record includes an impressive number of successful acquisitions and collaborations that have shaped the landscape of medical device technology. Cleary played a pivotal role in the strategic alliance between Orchestra BioMed and Medtronic, a collaboration focused on developing atrioventricular interval modulation (AVIM) therapy for managing hypertension, particularly in patients facing increased cardiovascular risks.
Strategic Collaborations and Innovations
David Hochman, the CEO and Chairman of Orchestra BioMed, expressed enthusiasm about Cleary's addition, stating, "Chris's vast experience in deal-making and global strategy will be invaluable as we strive to expand our unique partnership-enabled business model. His insight into high-impact medical devices is expected to enhance our path forward in bringing life-changing technologies to market." This sentiment echoes the company's commitment to fostering partnerships that enable remarkable innovations in patient care.
Vision for the Future
Christopher Cleary is equally excited about his new role, stating, "Joining the Board allows me to contribute to Orchestra BioMed's mission to accelerate medical device innovation in cardiovascular disease through strategic partnerships. The company's collaboration with Medtronic is a testament to its effective approach to overcoming challenges in therapy development by leveraging corporate resources efficiently. I look forward to collaborating with the talented team and Board of Directors to advance groundbreaking treatments like AVIM therapy and others that are yet to come."
Eric A. Rose's Transition and Continuing Influence
As Orchestra BioMed welcomes Christopher Cleary, it bids farewell to Eric A. Rose, M.D., who has served on the Board for seven years. Dr. Rose will transition to the role of Board Member Emeritus and Strategic Advisor, continuing to provide his valuable insights and guidance. His leadership in shaping the company’s strategic direction has been crucial, and his knowledge will remain an asset even in his new advisory capacity.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is dedicated to accelerating the commercialization of high-impact medical technologies through collaborative partnerships with leading companies in the medical device industry. Its innovative business model aims to transform the development and deployment of advanced healthcare solutions. The company’s flagship product, AVIM therapy, targets hypertension—a major global health challenge. Additionally, Orchestra BioMed is working on the Virtue Sirolimus AngioInfusion™ Balloon (SAB), aimed at treating atherosclerotic artery disease, which significantly impacts mortality rates worldwide.
Collaborative Partnerships
Orchestra BioMed's strategic alliance with Medtronic underscores its commitment to leveraging partnerships to push boundaries in medical device development. Another partnership with Terumo focuses on advancing the Virtue SAB to address atherosclerotic conditions effectively. These collaborations exemplify the company’s proactive approach to combining expertise and resources for impactful medical solutions.
Frequently Asked Questions
Who is Christopher Cleary?
Christopher Cleary is a seasoned executive with over 30 years of experience in the medical device industry. He has played significant roles in mergers, acquisitions, and strategic partnerships.
What is AVIM therapy?
AVIM therapy is an investigational treatment designed to lower blood pressure in patients with hypertension while using dual-chamber pacemakers. The therapy aims to provide innovative solutions for managing cardiovascular disease.
What role will Dr. Eric A. Rose play moving forward?
Dr. Eric A. Rose will transition to Board Member Emeritus and Strategic Advisor, continuing to provide guidance and expertise to Orchestra BioMed while stepping back from the active Board role.
How does Orchestra BioMed's business model work?
The company employs a partnership-enabled business model that emphasizes collaboration with other medical device companies to accelerate the commercialization of its innovative technologies.
What other products is Orchestra BioMed developing?
In addition to AVIM therapy, Orchestra BioMed is developing the Virtue SAB for the treatment of atherosclerotic artery disease, seeking to address some of the leading causes of mortality globally.
